Over the last decade the British Labour Government has presided over unprecedented increases in levels of spending on the National Health Service (NHS). But Opposition parties now claim that this record growth in NHS expenditure has been misspent, and some commentators are already predicting...

This paper considers the question of what ought to be valued in the context of measuring the outcomes of healthcare interventions. The answer is discrete health states in the case of the quality-adjusted life-year (QALY) model and an entire health profile in the case of the healthy-years...

It has been suggested by a number of economists that decisions about how to allocate scarce health care resources should be informed by the cost per quality-adjusted life-years (QALYs) of the different alternatives. One of the criticisms of the QALY approach is that it is based on the...

High levels of pathogen resistance are rendering current antibiotics obsolete. Coupled with insufficient investment in discovering new treatments, multidrug-resistant infections are an increasingly urgent public health concern. To curb the growth of antibiotic resistance and prevent major...

While recent research has explored the phenomenon of drug parallel trade in regulated environments such as the European Union (EU), or the European Economic Area, little is known about the mechanisms that explain its origin or the role of the distribution chain in exporting and importing...

This paper evaluates medicine prices, their availability and affordability in Brazil, considering the differences across three types of medicines on the market (originator brands, generics and similar medicines) and different types of facilities (private pharmacies, public sector pharmacies and...

This article uses panel data to investigate the extent of income-related inequity in the likelihood of visiting a General Practitioner (GP), specialist, dentist and hospital among individuals aged 65 years and over in the UK. The probability of accessing health care is predicted with separate...

This paper examines the arguments for changing the ways that UK drug prices are regulated. In the UK, NHS pharmaceutical expenditures on branded drugs, currently worth about £3 billion a year, have been regulated by the Pharmaceutical Price Regulation Scheme (PPRS) since 1978. We argue that, in...

The rise in health expenditure in the U.S. has generated interest in the determinants of health expenditure at the micro-level; however, individuals may exhibit differential behaviour across different types of health care. In addition, public and private insurance may have an heterogeneous...

The G8 is considering committing to purchase vaccines against diseases concentrated in low-income countries (if and when desirable vaccines are developed) as a way to spur research and development on vaccines for these diseases. Under such an advance market commitment, one or more sponsors would...